An Open-label, Multi-centre Registration Trial, Investigating Efficacy and Safety of Degarelix One-month Dosing Regimen in Taiwanese Patients With Prostate Cancer Requiring Androgen Ablation Therapy.
Phase of Trial: Phase III
Latest Information Update: 27 Jan 2014
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 07 Jun 2017 Biomarkers information updated
- 09 Oct 2012 Planned end date changed from 1 Jan 2013 to 1 Oct 2012 as reported by ClinicalTrials.gov.
- 08 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.